Syschem (India) Ltd is Rated Hold

Feb 15 2026 10:10 AM IST
share
Share Via
Syschem (India) Ltd is rated 'Hold' by MarketsMojo, with this rating last updated on 03 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Syschem (India) Ltd is Rated Hold

Current Rating and Its Significance

MarketsMOJO’s 'Hold' rating for Syschem (India) Ltd indicates a balanced outlook for investors. It suggests that while the stock presents certain attractive qualities, there are also factors that warrant caution. This rating advises investors to maintain their current holdings rather than aggressively buying or selling, reflecting a moderate risk-reward profile at present.

Quality Assessment

As of 15 February 2026, Syschem’s quality grade is assessed as average. The company’s return on equity (ROE) stands at 8.92%, which is modest and points to limited profitability relative to shareholders’ funds. This level of ROE indicates that while the company is generating returns, it is not yet delivering exceptional value on equity capital. Investors should note that this moderate efficiency in capital utilisation tempers expectations for rapid profit expansion solely from operational improvements.

Valuation Perspective

Currently, Syschem’s valuation is considered attractive. The stock trades at a price-to-book (P/B) ratio of approximately 2.4, which is below the average historical valuations of its peers in the Pharmaceuticals & Biotechnology sector. This discount suggests that the market is pricing the stock conservatively relative to its net asset value. Given the company’s strong recent profit growth, this valuation level may offer a margin of safety for investors seeking exposure to the sector without paying a premium.

Financial Trend and Performance

The latest data shows an outstanding financial trend for Syschem. Net sales have grown at an impressive annual rate of 47.95%, reflecting robust top-line expansion. Quarterly net sales reached ₹141.50 crores, marking an 81.97% increase, while profit after tax (PAT) surged by 734% to ₹4.17 crores in the latest quarter. The company has reported positive results for five consecutive quarters, underscoring a sustained upward trajectory in earnings.

Moreover, the company maintains a very low debt-to-EBITDA ratio of 0.09 times, indicating a strong ability to service its debt and a conservative capital structure. This financial strength reduces risk and provides flexibility for future growth initiatives.

Technical Outlook

From a technical standpoint, the stock exhibits mildly bearish signals. Recent price movements show a 1-day decline of 2.46% and a 3-month dip of 8.07%, despite a positive 1-month return of 3.49% and a 6-month gain of 9.11%. Year-to-date, the stock has appreciated by 9.63%, and over the past year, it has delivered a 7.74% return. These mixed technical indicators suggest some short-term volatility, which investors should monitor closely.

Stock Returns and Market Performance

As of 15 February 2026, Syschem’s stock performance reflects moderate gains amid sector volatility. The 1-year return of 7.74% is respectable given the broader market conditions and the company’s microcap status. The stock’s price movement aligns with its fundamental improvements, particularly the substantial profit growth, although technical factors have introduced some near-term pressure.

Investor Considerations

For investors, the 'Hold' rating signals a need for measured optimism. The company’s strong financial trend and attractive valuation provide a solid foundation, but the average quality grade and mildly bearish technical outlook suggest that the stock may not yet be poised for significant upside momentum. Investors should weigh these factors carefully, considering their risk tolerance and investment horizon.

This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.

  • - Target price included
  • - Early movement detected
  • - Complete analysis ready

Get Complete Analysis Now →

Company Profile and Market Context

Syschem (India) Ltd operates within the Pharmaceuticals & Biotechnology sector and is classified as a microcap company. The sector is known for its growth potential but also for volatility and regulatory risks. The company’s majority shareholders are promoters, which often indicates stable ownership and strategic direction.

Summary of Key Metrics

To summarise, as of 15 February 2026:

  • Mojo Score stands at 60.0, reflecting a Hold grade.
  • Quality Grade: Average, with ROE at 8.92%.
  • Valuation Grade: Attractive, with a P/B ratio of 2.4.
  • Financial Grade: Outstanding, driven by strong sales and profit growth.
  • Technical Grade: Mildly Bearish, with recent price declines.
  • Stock returns over 1 year: +7.74%.

What This Means for Investors

The 'Hold' rating reflects a nuanced view of Syschem’s current investment appeal. While the company demonstrates excellent financial momentum and attractive valuation, the moderate quality and technical caution advise investors to maintain existing positions rather than pursue aggressive buying. This balanced stance helps investors avoid undue risk while remaining positioned to benefit from the company’s ongoing growth.

Looking Ahead

Investors should continue to monitor Syschem’s quarterly results and market developments closely. Key indicators to watch include improvements in management efficiency, further profit growth, and any shifts in technical trends. Maintaining a disciplined approach aligned with the 'Hold' rating will help investors navigate the stock’s evolving profile.

Conclusion

Syschem (India) Ltd’s current 'Hold' rating by MarketsMOJO, last updated on 03 February 2026, is supported by a combination of solid financial performance, attractive valuation, and cautious technical signals. As of 15 February 2026, the stock presents a balanced investment proposition suitable for investors seeking steady exposure to the Pharmaceuticals & Biotechnology sector without excessive risk.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News